Flexibility Fails Before Memory Does

The field has spent two decades building diagnostic infrastructure, pharmaceutical pipelines, and clinical trial designs around a single assumption. Memory loss is the entry point to Alzheimer's disease.

A neurological shift is now challenging that assumption. Emerging research suggests cognitive flexibility—the capacity to move your thinking from one task to another, to adjust strategy when conditions change—deteriorates before memory does.

This matters because assumptions, once embedded in screening protocols and test designs, become invisible. They stop looking like choices and start looking like facts. Doctors screen for memory impairment because decades of clinical data show that memory-impaired patients develop Alzheimer's. But clinical convenience is not the same as mechanistic primacy.

An early warning signal can become the standard measure simply because it's measurable and repeatable, even if it's not the first thing to break. Consider the Framingham Heart Study. Tracked cardiovascular risk for generations by measuring cholesterol and blood pressure—useful markers that shaped global health policy for fifty years. But those markers succeeded because they predicted outcomes, not because they captured what was actually breaking in the vessel wall.

With Alzheimer's, flexibility loss might work the same way. A patient who can no longer shift between mental tasks, who perseverates on one thought or struggle to adapt to conversation shifts, looks cognitively intact on a memory test. They pass. They go unscreened. They progress.

If it does, then twenty years of diagnostic infrastructure was built on a premise nobody ever tested. If it doesn't, we've been doing it right for reasons we didn't fully understand. Either way, we were guessing.